Benign Prostatic Hyperplasia Therapeutics Market Expected to Hit $ 20,097 Million by 2025, Growing at a CAGR of 8.1%
According to the Benign Prostatic Hyperplasia Therapeutics Market based on Allied Market Research's Therapeutics Class and Therapy: Global Opportunity Analysis and Industry Outlook (2018-2025), the market size was $ 10,689 million in 2017 and reached $ 20,097 million in 2025 With an annual average growth rate of 8.1% from 2018 to 2025.Benign prostatic hyperplasia (BPH) is a medical condition in which a male’s prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708
Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.
The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.
The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.
Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4708
Key findings of the Benign Prostatic Hyperplasia Therapeutics Market:
• The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.
• The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.
• Europe accounted for around one-third share of the global market in 2017.
• LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.
North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017 and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.
Access Full Summery @ https://www.alliedmarketresearch.com/benign-prostatic-hyperplasia-therapeutics-market
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Market Expected to Hit $ 20,097 Million by 2025, Growing at a CAGR of 8.1% here
News-ID: 1770580 • Views: …
More Releases from Allied Market Research
Gardening Equipment Market Exhibit a Remarkable CAGR of 6.2% and is expected to …
Gardening Equipment Market by Product Type (Lawn Mowers, Handheld equipment, Others), by End-User (Residential, Commercial), by Sales Channel (Online, Offline): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global gardening equipment industry generated $40.40 billion in 2021, and is anticipated to generate $74.97 billion by 2031, witnessing a CAGR of 6.2% from 2022 to 2031.
Download Sample PDF:
https://www.alliedmarketresearch.com/request-sample/A07856
Prime determinants of growth
Rapid industrialization & urbanization, surge in middle-class…
2030 Forecast | Micro Motor Market Growing at 4.1% CAGR and Expected to reach $5 …
Micro Motor Market by Type (AC and DC), Technology (Brushed Motor and Brushless Motor), Power Consumption (Less Than 10V, 10V-20V, and More Than 20V), and Application (Industrial, Automotive & Aerospace, Healthcare, and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global micro motor industry generated $36.47 billion in 2020, and is estimated to generate $56.06 billion by 2030, witnessing a CAGR of 4.1% from 2021…
Cross Laminated Timber Market Exhibit a Remarkable CAGR of 8.4% and is expected …
The growth of the global cross laminated timber market is driven by growth of the building construction industry, the rise in demand for sustainable construction materials, and various advantages of cross-laminated timber.
Cross Laminated Timber Market By Layer Type (3-Ply, 5-Ply, and Other), By Structure Type (Wall, Roof And Floor, and Other), By Application (Residential, and Non-Residential): Global Opportunity Analysis And Industry Forecast, 2023-2032". The cross laminated timber market was valued…
Marine Gel Coat Market Size 2024, Industry Share, CAGR, Regional Forecast 2032
According to the report, the global marine gel coat market generated $4.2 billion in 2022, and is anticipated to generate $7.5 billion by 2032, rising at a CAGR of 6.1% from 2023 to 2032.
Allied Market Research has recently published a report, titled, "Marine Gel Coat Market Size, Share, Competitive Landscape and Trend Analysis Report by Gelcoat Type, by Resin Type: Global Opportunity Analysis and Industry Forecast, 2023-2032."
…
More Releases for Benign
Benign Prostatic Hyperplasia Therapeutics Market Clinical Survey Report 2020
The Benign Prostatic Hyperplasia Therapeutics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Click the link…
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.…
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot
Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded.
Cold plasma isn't in…
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants…
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports.
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices.
Topics Covered Include:
An overview of device-based and pharmacological therapies for BPH and prostatitis.
Global and country/region-specific market forecasts, including forecasts by product segment.
Competitive analyses…
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 …
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a…